Skip to main content
. 2024 Feb 24;20:200250. doi: 10.1016/j.ijcrp.2024.200250

Table 1.

Patient characteristics.

Group A
DM (−) elevated TyG index (−) n = 281
Group B
DM (−) elevated TyG index (+) n = 232
Group C
DM (+) n = 171
p-value
Age, years 65 (12) 64 (12) 67 (10) 0.064
Male, n (%) 150 (65%) 143 (62%) 123 (72%) <0.001
BMI, kg/mm2 23.1 (3.7) 24.5 (4.2) 24.5 (4.1) <0.001
Hypertension, n (%) 196 (70%) 181 (78%) 153 (89%) <0.001
Dyslipidemia, n (%) 158 (56%) 190 (82%) 136 (80%) <0.001
Systolic BP, mmHg 140 (20) 141 (22) 145 (22) 0.097
Heart rate, beats/min 76 (14) 76 (13) 78 (13) 0.246
Current or past smoker, n (%) 75 (27%) 69 (30%) 48 (28%) 0.746
Atrial fibrillation, n (%) 21 (7.4%) 14 (6.0%) 17 (9.9%) 0.350
Laboratory parameters
 Triglyceride, mg/dL 90 (70–111) 176 (145–223) 126 (81–167) <0.001
 HDL-C, mg/dL 70 (19) 56 (16) 57 (17) <0.001
 LDL-C, mg/dL 117 (34) 127 (38) 107 (34) <0.001
 Fasting plasma glucose, g/dL 104 (18) 119 (31) 159 (67) <0.001
 HbA1c, % 5.6 (0.3) 5.8 (0.3) 7.0 (1.4) <0.001
 CRP, mg/L 0.7 (0.3–1.7) 1.2 (0.5–2.6) 0.9 (0.4–2.7) 0.013
 TyG index, median (IQR) 8.4 (8.2–8.6) 9.2 (9.0–9.5) 9.1 (8.6–9.5) <0.001
 eGFR, mL/min/1.73 mm2 67 (15) 67 (16) 64 (15) 0.202
Medication
 ACE inhibitor or ARB, n (%) 63 (22%) 65 (28%) 68 (40%) <0.001
 Calcium channel blocker, n (%) 75 (27%) 59 (25%) 67 (39%) 0.005
 β-blocker, n (%) 25 (8.8%) 19 (8.2%) 23 (13%) 0.172
 Statins, n (%) 69 (25%) 69 (30%) 81 (47%) <0.001
 Oral antidiabetic drugs, n (%) 0 (0%) 0 (0%) 104 (61%)
 Insulin, n (%) 0 (0%) 0 (0%) 7 (4.1%)

Values are presented as mean (standard deviation) or number (%).

ACE, angiotensin converting enzyme; ARB, angiotensin Ⅱ receptor blocker; BMI, body mass index; BP, blood pressure; CRP, C-reactive protein; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; IQR, interquartile range; TyG, triglyceride glucose; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein.